Advancing PAN-RAS Inhibitors: Tackling Mutational Heterogeneity in Diverse Cancers Using Cutting-Edge Modalities
Time: 9:45 am
day: Day One
Details:
- Alternatives to small-molecule drugs for mutant KRAS targeting
- Rationale for bacteria-mediated intracellular delivery of single-domain antibodies (VHH) as a next-generation therapy
- Introducing SVC-KRAb: a first-in-class pan-KRAS-targeting therapeutic
